Vitra Bioscience said last week that it has raised $5.5 million in a second round of financing and plans to use this new cash infusion to push its flagship CellCard assay technology to market.

The fundraising effort comes three years after an initial round of financing yielded a little over $9 million for the company, which at that point was called Virtual Arrays. And early last year, the Mountain View, Calif.-based company was awarded a Phase I SBIR grant by the National Cancer Institute to further develop CellCard.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.